Stocks›Healthcare

Accretion Nutraveda Limited

ANL · BSE · Healthcare · As of 8 Nov 2026

₹331.00

+₹2.00 (+0.61%)(1D)

₹150.10Since listing range₹348.00

Market Cap

₹239.64 Cr

P/E (Sector)

35.4 (32.3)

P/B Ratio

—

Dividend Yield

—

ROE

70.0%

Debt / Equity

—

Anvest Score

67/100

Valuation

0/100

Quality

100/100

Growth

53/100

Health

100/100

Momentum

93/100

Valuation
0
Quality
100
Growth
53
Health
100
Momentum
93

AI Company ProfileFiling-backed

AI Snapshot

Founded in 2021, it operates within the healthcare sector in India, aiming to capture a share of the growing health and wellness market.

PharmaceuticalsFounded:2021CEO/MD:Mayur Popatlal SojitraHQ:Ahmedabad, Gujarat

Business profile as of period ended 25 Aug 2026

Revenue growth: +110.0%FY26 growth+126.3%3Y CAGR
PAT growth: +94.3%FY26 growth+162.6%3Y CAGR

What Looks Strong

GrowthRevenue and net profit grew at +126% and +163% 3Y CAGR (FY23 base from pre-listing restated prospectus financials).
IPOShares trade +143.7% above the ₹119 IPO issue price.

What to Watch

HistoryShort public market track record with limited historical filing cycles.

Loading company profile…

Fundamentals

P/E Ratio (TTM)

35.4

Sector median P/E

32.29

P/B Ratio

—

Sector median P/B

4.4

EPS (TTM)

₹9.35

Market Cap

₹239.64 Cr

ROE

70.03%

ROCE

93.09%

Profit Margin

15.04%

Accretion Nutraveda Limited FAQs

3 topics

Expand

What does the Accretion Nutraveda Limited (ANL) stock page cover?

Accretion Nutraveda Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for ANL?

Accretion Nutraveda Limited is currently shown with a delayed price near ₹331, P/E 35.4, and ROE 70.03%.

Does the ANL page provide investment advice?

No. The ANL page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring